Last reviewed · How we verify
EMD 72000
EMD 72000 is a monoclonal antibody targeting PD-L1.
EMD 72000 is a monoclonal antibody targeting PD-L1. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | EMD 72000 |
|---|---|
| Sponsor | EMD Serono |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by blocking the PD-L1 protein, which is involved in the immune system's regulation of cancer cell growth. This allows the immune system to recognize and attack cancer cells more effectively.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Rash
- Pneumonitis
Key clinical trials
- A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (PHASE2)
- A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations (PHASE3)
- A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC (PHASE2)
- A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression (PHASE2)
- The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) (PHASE2)
- HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors (PHASE1)
- A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer (PHASE2)
- HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EMD 72000 CI brief — competitive landscape report
- EMD 72000 updates RSS · CI watch RSS
- EMD Serono portfolio CI